mtc

(redirected from Medullary thyroid cancer)
Also found in: Medical.

mtc

A Modula-2 to C translator.

ftp://rusmv1.rus.uni-stuttgart.de/soft/Unixtools/compilerbau/mtc.tar.Z.

MTC

(Machine Type Communications) Cellular transmission from machines rather than people. MTC was coined by the 3G/4G term (see 3GPP).
References in periodicals archive ?
Medullary thyroid cancer is a malignancy of the parafollicular cells and is often seen in such syndromes as multiple endocrine neoplasia (MEN).
Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Medullary Thyroid Cancer therapeutics.
It also inhibits RET kinase, an important growth factor in medullary thyroid cancer.
Exelixis submitted a new drug application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer to the United States Food and Drug Administration.
AstraZeneca plans regulatory submissions in 2010 for the treatment of patients with advanced medullary thyroid cancer.
Individuals in MEN 2A families carrying the defective gene may have a near-100% risk of medullary thyroid cancer, the penetrance being age-related [12].
It is currently in Phase III trials for two indications: medullary thyroid cancer and metastatic castrate-resistant prostate cancer.
LONDON, June 7, 2010 /PRNewswire/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.
Gardner's strategy is to biopsy lesions in high-risk patients, whom he defined as those with a history of childhood head or neck irradiation, those with a family history of papillary of medullary thyroid cancer, and those with suspicious findings on ultrasound.
NASDAQ: EXEL) today was notified by the Food and Drug Administration (the "FDA") that the Company's new drug application ("NDA") for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer has been removed from the agenda for the November 8 and November 9, 2012 meeting of the FDA's Oncologic Drugs Advisory Committee ("ODAC").
A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.
Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).